Please upgrade your browser.
Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.
The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized.
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival
CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis...
We report a 13-year-old white girl with epilepsy and hypopigmented skin lesions...
Life experience doesn't prepare you for cancer caregiving.
Genetics can sometimes explain why some people respond well to a drug whereas others may experience serious side effects. The InVite Study is a collaborative effort between 23andMe and Genentech to learn more about how genes influence response to bevacizumab (also known as Avastin®) in the treatment of locally recurrent or metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, or metastatic renal cell carcinoma.
Cancer is a leading cause of death worldwide. In 2008, it was the cause of 7.6 million deaths globally, and it is estimated that a third of those deaths could have been avoidable with greater prevention, early detection and existing treatments.
Shrive was one of seven finalists this year and becomes the fifth recipient of the award.
David participated in a Phase 2 clinical study that evaluated a personalized cancer immunotherapy in combination with a standard targeted drug therapy, sunitinib.
Emails Tell the Story of the NCI Cancer Bulletin
|NeonCRM by Neon One|